Search Result

Results for "

fibrinogen binding

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (9) Interleukin Related (2) Reference Standards (2) RSV (2) Thrombin (3)
By Research Areas:	Cardiovascular Disease (15) Infection (2) Inflammation/Immunology (2)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Targets Recommended: Emopamil Binding Protein Penicillin-binding protein (PBP) Cdc42-binding kinase ATP-binding cassette (ABC) transporters Oxysterol-binding Protein-related Protein (ORP) FKBP FABP Transthyretin (TTR) Ligands for Target Protein for PROTAC YB-1 SDCBP GHR P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1741

Fibrinogen-Binding Peptide 1 Publications Verification	Thrombin	Cardiovascular Disease
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-P1741A

Fibrinogen-Binding Peptide TFA 1 Publications Verification	Integrin	Cardiovascular Disease
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-P1507

Fibrinogen Binding Inhibitor Peptide	Integrin	Cardiovascular Disease
Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P1929

Bivalirudin Maximum Cited Publications 8 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-17369B

Tirofiban 4 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369

Tirofiban hydrochloride monohydrate 4 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-15664

Bivalirudin TFA Maximum Cited Publications 8 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-118410

L-738167	Integrin	Cardiovascular Disease
L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369R

Tirofiban hydrochloride monohydrate (Standard) L700462 hydrochloride monohydrate (Standard); MK383 hydrochloride monohydrate (Standard)	Reference Standards Integrin	Cardiovascular Disease
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369BR

Tirofiban (Standard) L700462 (Standard); MK383 (Standard)	Reference Standards Integrin	Cardiovascular Disease
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-167848

DMP-728 free base XL-118	Others	Cardiovascular Disease
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC₅₀ of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .

Cat. No.	Product Name	Target	Research Area

HY-P1741

Fibrinogen-Binding Peptide 1 Publications Verification	Thrombin	Cardiovascular Disease
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-P1741A

Fibrinogen-Binding Peptide TFA 1 Publications Verification	Integrin	Cardiovascular Disease
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .

HY-P1507

Fibrinogen Binding Inhibitor Peptide	Integrin	Cardiovascular Disease
Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.

HY-P0314A

Arg-Gly-Asp-Cys TFA	Peptides	Cardiovascular Disease
Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding .

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P1929

Bivalirudin Maximum Cited Publications 8 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-15664

Bivalirudin TFA Maximum Cited Publications 8 Publications Verification	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-P5991

K-Casein (106-116),bovine	Peptides	Cardiovascular Disease
K-Casein (106-116),bovine is a peptide that inhibits platelet aggregation and fibrinogen binding, plays an important role in atherosclerosis .

HY-P0314

Arg-Gly-Asp-Cys	Peptides	Others
Arg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.

HY-P4278

H-Gly-His-Arg-Pro-NH2	Peptides	Others
H-Gly-His-Arg-Pro-NH2 (GHRP-amide) is composed of L-prolinamide, glycine, L-histidine, L-arginine, and participates in the binding of desAB-NDSK to fibrinogen .

Species:	Human (1) Staphylococcus aureus (3)
Tag:	His (3) SUMO (1) Tag Free (1)
Source:	P. pastoris (2) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P72291

	Clumping factor B Protein, S. aureus (His, SUMO) fibrinogen receptor B; fibrinogen-binding protein B	Staphylococcus aureus	E. coli
	Clumping factor B (ClfB) is a cell surface-associated protein implicated in virulence, playing a crucial role in bacterial pathogenicity by promoting bacterial attachment to both alpha- and beta-chains of human fibrinogen. Its significance lies in inducing the formation of bacterial clumps, a mechanism that contributes to the pathogenicity and virulence of the bacteria. Clumping factor B Protein, S. aureus (His, SUMO) is the recombinant Staphylococcus aureus-derived Clumping factor B protein, expressed by E. coli , with N-6*His-SUMO labeled tag.

HY-P71581

	Clumping factor A Protein, S. aureus clfA; SAS0752; Clumping factor A; fibrinogen receptor A; fibrinogen-binding protein A	Staphylococcus aureus	E. coli
	Clustering factor A (ClfA) is a virulence-related cell surface-associated protein that plays a key role in bacterial pathogenicity. It promotes bacterial attachment exclusively to the gamma chain of human fibrinogen, demonstrating the specificity of its interaction with host proteins. Clumping factor A Protein, S. aureus is the recombinant Staphylococcus aureus-derived Clumping factor A protein, expressed by E. coli , with tag free.

HY-P702865

	FCN2 Protein, Human (P.pastoris, His) Ficolin-2; 37 kDa elastin-binding protein; Collagen/fibrinogen domain-containing protein 2; EBP-37; Ficolin-B; Ficolin-beta; FCNL	Human	P. pastoris
	FCN2 Protein, Human (P.pastoris, His) is the recombinant human-derived FCN2, expressed by P. pastoris , with N-6*His labeled tag.

HY-P71829

	Clumping factor A Protein, S. aureus (P.pastoris, His) clfA; fibrinogen receptor A; fibrinogen-binding protein A	Staphylococcus aureus	P. pastoris
	Clumping factor A protein facilitates bacterial attachment to human fibrinogen gamma-chain, promoting the formation of bacterial clumps. It is a cell surface-associated protein and plays a role in bacterial virulence. Clumping factor A Protein, S. aureus (P.pastoris, His) is the recombinant Staphylococcus aureus-derived Clumping factor A protein, expressed by P. pastoris , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.